The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase l study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high grade glioma.
A. F. Hottinger
Research Funding - Bayer
A. Ben Aissa
No relevant relationships to disclose
A. Bodmer
No relevant relationships to disclose
D. Squiban
No relevant relationships to disclose
N. Dunkel
No relevant relationships to disclose
N. Maradan
Employment or Leadership Position - Bayer
M. I. Vargas
No relevant relationships to disclose
D. C. Weber
No relevant relationships to disclose
E. Brendel
Employment or Leadership Position - Bayer
P. Dietrich
Research Funding - Bayer